Generation of a model of l-DOPA-induced dyskinesia in two different mouse strains

Journal of Neuroscience Methods

Volumn 197, Issue 2, 2011, Pages 193-208

  Thiele, Sherri L ^a   Warre, Ruth ^a   Khademullah, Charline S ^a   Fahana, Nusrat ^a   Lo, Charlotte ^a   Lam, Doris ^a   Talwar, Sheena ^a   Johnston, Tom H ^b   Brotchie, Jonathan M ^b   Nash, Joanne E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

6 OHDA; BAC mice; Dyskinesia; L DOPA; Medial forebrain bundle; Mouse strain

Indexed keywords

DOPAMINE; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DYSKINESIA; IMMUNOHISTOCHEMISTRY; MOUSE; MOUSE STRAIN; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; STRAIN DIFFERENCE; SURGICAL MORTALITY;

ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; EFFERENT PATHWAYS; LEVODOPA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 79955045279     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2011.02.012     Document Type: Article

References (59)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16(3):448-458.
2. Ahmed M.R., Berthet A., Bychkov E., Porras G., Li Q., Bioulac B.H., et al. Lentiviral overexpression of GRK6 alleviates l-DOPA-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med 2010, 2. 28ra28.
3. Altman D.G., Bland J.M. Statistics notes: diagnostic tests 1: sensitivity and specificity. BMJ 1994, 308:1552.
4. Bedard P.J., Di Paolo T., Falardeau P., Boucher R. Chronic treatment with l-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res 1986, 379(2):294-299.
5. Belujon P., Lodge D.J., Grace A.A. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment. Mov Disord 2010, 25(11):1568-1576.
6. Besson M.J., Graybiel A.M., Nastuk M.A. [3H]SCH 23390 binding to D1 dopamine receptors in the basal ganglia of the cat and primate: delineation of striosomal compartments and pallidal and nigral subdivisions. Neuroscience 1988, 26(1):101-119.
7. Birkmayer W., Hornykiewicz O. The l-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 1961, 73:787-788.
8. Boraud T., Bezard E., Bioulac B., Gross C.E. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 2001, 124(Pt 3):546-557.
9. Brotchie J.M. Novel approaches to the symptomatic treatment of parkinsonian syndromes: alternatives and adjuncts to dopamine-replacement. Curr Opin Neurol 1997, 10(4):340-345.
10. Cenci M.A., Lee C.S., Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998, 10(8):2694-2706.
11. Cenci M.A., Lundblad M. Ratings of l-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci 2007, 41. 9.25.1-9.25.23.
12. Clarke C.E., Sambrook M.A., Mitchell I.J., Crossman A.R. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 1987, 78(3):273-280.
13. Costall B., Naylor R.J., Pycock C. Non-specific supersensitivity of striatal dopamine receptors after 6-hydroxydopamine lesion of the nigrostriatal pathway. Eur J Pharmacol 1976, 35(2):276-283.
14. Darmopil S., Martin A.B., Ruiz De Diego I., Ares S., Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits l-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 2009, 66(6):603-613.
15. Darmopil S., Muneton-Gomez V.C., de Ceballos M.L., Bernson M., Moratalla R. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by l-DOPA. Eur J Neurosci 2008, 27:580-592.
16. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39(6):889-909.
17. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 2007, 179(1):76-89.
18. Emborg M.E. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J Neurosci Methods 2004, 139(2):121-143.
19. Fasano S., Bezard E., D'Antoni A., Francardo V., Indrigo M., Qin L., et al. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with l-DOPA-induced dyskinesia. PNAS 2010, 107(50):21824-21829.
20. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 2007, Academic Press.
21. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990, 250(4986):1429-1432.
22. Ghiglieri V., Picconi B., Calabresi P. Direct and indirect pathways in levodopa-induced dyskinesia: a more complex matter than a network imbalance. Mov Disord 2010, 25(11):1527-1529.
23. Gong S., Zheng C., Doughty M.L., Losos K., Didkovsky N., Schambra U.B., et al. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 2003, 425(6961):917-925.
24. Guigoni C., Bezard E. Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in l-DOPA-induced dyskinesia. Parkinsonism Relat Disord 2009, 15(Suppl. 3):S64-S67.
25. Henry B., Crossman A.R., Brotchie J.M. Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of l-DOPA-induced dyskinesia. Adv Neurol 1998, 78:53-61.
26. Henry B., Crossman A.R., Brotchie J.M. Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998, 151(2):334-342.
27. Hutchison W.D., Lozano A.M., Davis K.D., Saint-Cyr J.A., Lang A.E., Dostrovsky J.O. Differential neuronal activity in segments of globus pallidus in Parkinson's disease patients. Neuroreport 1994, 5(12):1533-1537.
28. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007, 2(1):141-151.
29. Kreitzer A.C., Malenka R.C. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007, 445(7128):643-647.
30. Lee C.S., Cenci M.A., Schulzer M., Björklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 2000, 123(7):1365-1379.
31. Lucarelli C., Betto P., Ricciarello G., Grossi G. High-performance liquid chromatographic determination of l-3-(3,4-dihydroxyphenyl)-2-methylalanine (alpha-methyldopa) in human urine and plasma. J Chromatogr 1991, 541(1-2):285-296.
32. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002, 15(1):120-132.
33. Lundblad M., Picconi B., Lindgren H., Cenci M.A. A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2004, 16(1):110-123.
34. Lundblad M., Usiello A., Carta M., Hakansson K., Fisone G., Cenci M.A. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 2005, 194(1):66-75.
35. Maneuf Y.P., Mitchell I.J., Crossman A.R., Brotchie J.M. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol 1994, 125(1):65-71.
36. Marsden C.D., Parkes J.D. " On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976, 1(7954):292-296.
37. Nash J.E., Johnston T.H., Collingridge G.L., Garner C.C., Brotchie J.M. Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and l-DOPA-induced dyskinesia. FASEB J 2005, 19(6):583-585.
38. Nicholas A.P. Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Mov Disord 2007, 22(1):99-104.
39. Pan H.S., Penney J.B., Young A.B. Gamma-aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle. J Neurochem 1985, 45(5):1396-1404.
40. Pan H.S., Walters J.R. Unilateral lesion of the nigrostriatal pathway decreases the firing rate and alters the firing pattern of globus pallidus neurons in the rat. Synapse 1988, 2(6):650-656.
41. Papa S.M., Desimone R., Fiorani M., Oldfield E.H. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol 1999, 46(5):732-738.
42. Paul G., Meissner W., Rein S., Harnack D., Winter C., Hosmann K., et al. Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease. Exp Neurol 2004, 185(2):272-280.
43. Picconi B., Paillé V., Ghiglieri V., Bagetta V., Barone I., Lindgren H.S., et al. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 2008, 29(2):327-335.
44. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., et al. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat Neurosci 2003, 6(5):501-506.
45. Pisani A., Shen J. Levodopa-induced dyskinesia and striatal signaling pathways. PNAS 2009, 106(9):2973-2974.
46. Putterman D.B., Munhall A.C., Kozell L.B., Belknap J.K., Johnson S.W. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2007, 323(1):277-284.
47. Ravenscroft P., Chalon S., Brotchie J.M., Crossman A.R. Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp Neurol 2004, 185(1):36-46.
48. Robertson G.S., Robertson H.A. Evidence that l-DOPA-induced rotational behavior is dependent on both striatal and nigral mechanisms. J Neurosci 1989, 9(9):3326-3331.
49. Santini E., Valjent E., Usiello A., Carta M., Borgkvist A., Girault J.A., et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in l-DOPA-induced dyskinesia. J Neurosci 2007, 27(26):6995-7005.
50. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39(5):777-787.
51. Schiffmann S.N., Jacobs O., Vanderhaeghen J.J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991, 57(3):1062-1067.
52. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001, 125(1-2):109-125.
53. Shen W., Flajolet M., Greengard P., Surmeier D.J. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008, 321(5890):848-851.
54. Tan Y., Williams E.A., Lancia A.J., Zahm D.S. On the altered expression of tyrosine hydroxylase and calbindin-D 28kD immunoreactivities and viability of neurons in the ventral tegmental area of Tsai following injections of 6-hydroxydopamine in the medial forebrain bundle in the rat. Brain Res 2000, 869(1-2):56-68.
55. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24(3):485-493.
56. Visanji N.P., Orsi A., Johnston T.H., Howson P.A., Dixon K., Callizot N., et al. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J 2008, 22(7):2488-2497.
57. Warre R., Thiele S., Talwar S., Kamal M., Johnston T.H., Wang S., et al. Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism. Neurobiol Dis 2011, 41(3):591-604.
58. Winkler C., Kirik D., Bjorklund A., Cenci M.A. l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2002, 10(2):165-186.
59. 2A receptors contribute to l-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci 2006, 26(52):13548-13555.